Antagonism of thromboxane receptors by diclofenac and lumiracoxib (British Journal of Pharmacology (2008) 152: 8 (1185-1195) doi: 10.1038/sj.bjp.0707518);Antagonism of thromboxane receptors by diclofenac and lumiracoxib

British Journal of Pharmacology

Volumn 152, Issue 8, 2007, Pages 1185-1195

  Selg, E ^a   Buccellati, C ^b   Andersson, M ^a   Rovati, G E ^b   Ezinga, M ^a   Sala, A ^b   Larsson, A K ^a   Ambrosio, E ^b   Lastbom L ^a   Capra, V ^b   Dahlen B ^a   Ryrfeldt, A ^a   Folco, G C ^b   Dahlen S E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Airway smooth muscle; Cyclooxygenase inhibitors; Guinea pig lung; Human platelet aggregation; Vascular smooth muscle

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; CELECOXIB; DICLOFENAC; FLURBIPROFEN; LUMIRACOXIB; OZAGREL; PROSTAGLANDIN D2; ROFECOXIB; THROMBOXANE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE;

EID: 36949016433     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.106     Document Type: Erratum

References (40)

1. Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL et al. (2000). Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 101: 2833-2840.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528.
3. Born GV, Cross MJ (1963). The aggregation of blood platelets. J Physiol 168: 178-195.
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.
5. Capra V, Habib A, Accomazzo MR, Ravasi S, Citro S, Levy-Toledano S et al. (2003). Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation. Eur J Pharmacol 474: 149-159.
6. Capra V, Veltri A, Foglia C, Crimaldi L, Habib A, Parenti M et al. (2004). Mutational analysis of the highly conserved ERY motif of the thromboxane A2 receptor: alternative role in G protein-coupled receptor signaling. Mol Pharmacol 66: 880-889.
7. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T et al. (2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541.
8. Collier HOJ, Hammond AR, Whiteley B (1963). Anti-anaphylactic action of acetylsalicylate in guinea pig lung. Nature 200: 176-178.
9. Drazen JM, Schneider MW(1978). Comparative responses of tracheal spirals and parenchymal strips to histamine and carbachol in vitro. J Clin Invest 61: 1441-1447.
10. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA et al. (2005). Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144: 538-550.
11. Evans AR, Junger H, Southall MD, Nicol GD, Sorkin LS, Broome JT et al. (2000). Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons. J Pharmacol Exp Ther 293: 912-920.
12. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ et al. (2004). Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675-684.
13. Featherstone RL, Robinson C, Holgate ST, Church MK (1990). Evidence for thromboxane receptor mediated contraction of guinea-pig and human airways in vitro by prostaglandin (PG) D2, 9 alpha,11 beta-PGF2 and PGF2 alpha. Naunyn Schmiedebergs Arch Pharmacol 341: 439-443.
14. FitzGerald GA, Patrono C (2001). The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345: 433-442.
15. Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS et al. (2005). Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2: 201-207.
16. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990). The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737-16740.
17. Grosser T, Fries S, FitzGerald GA (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15.
18. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A et al. (1998). Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 352: 1016-1021.
19. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM et al. (2001). Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104: 820-825.
20. Juni P, Rutjes AW, Dieppe PA (2002). Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 324: 1287-1288.
21. Lyseng-Williamson KA, Curran MP (2004). Lumiracoxib. Drugs 64: 2237-2246; discussion 2247-2248.
22. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999). Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277.
23. Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, Warner TD (2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 20: 2468-2475.
24. Morrow J, Hill K, Burk R, Nammour T, Badr K, Roberts LJI (1990). A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed-mechanism. Proc Natl Acad Sci USA 87: 9383-9387.
25. Munson PJ, Rodbard D (1980). Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220-239.
26. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL et al. (2005). Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091.
27. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M (1985). Pharmacological actions of SQ 29548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 234: 435-441.
28. Paulose-Ram R, Hirsch R, Dillon C, Gu Q (2005). Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among US adults. Pharmacoepidemiol Drug Saf 14: 257-266.
29. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255.
30. Smith JB, Willis AL (1971). Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 231: 235-237.
31. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al. (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080.
32. Sundstrom E, Lastbom L, Ryrfeldt A, Dahlen S-E (2003). Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung. J Pharmacol Exp Ther 307: 408-418.
33. Takayama K, Yuhki K, Ono K, Fujino T, Hara A, Yamada T et al. (2005). Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med 11: 562-566.
34. Thomas DW, Rocha PN, Nataraj C, Robinson LA, Spurney RF, Koller BH et al. (2003). Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. J Immunol 171: 6389-6395.
35. Todd PA, Sorkin EM (1988). Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 35: 244-285.
36. Vane JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232-235.
37. Wallace JL (2001). Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 15: 691-703.
38. Whittle BJ (2003). Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 17: 301-313.
39. Wolfe MM, Lichtenstein DR, Singh G (1999). Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899.
40. Worth NF, Berry CL, Thomas AC, Campbell JH (2005). S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 183: 65-73.